Elaszym has shown multi-target therapeutic effects in chronic inflammation and metabolic diseases, and its discontinuation needs to be gradually adjusted according to the course of treatment and individual response. The following provides a detailed explanation from two aspects: evaluation of treatment efficacy and precautions for discontinuing medication.

1. Evaluation of treatment efficacy

(1) Chronic bronchitis: Clinical data shows that continuous medication for 4 weeks can reduce sputum viscosity by 40% -50% and cough frequency by about 35%.

(2) Atherosclerosis: After 6 months of treatment, the average ankle brachial index of the patient improved by 0.15, and the distance of intermittent claudication increased by 30% -45%.

(3) Hyperlipidemia: Adjuvant treatment for 3 months can reduce TC by 15% -20% and LDL-C by 18% -25%, which is more effective than using statins alone.

2. Precautions for discontinuation of medication

(1) Standard discontinuation process

If the treatment duration is ≤ 3 months, the medication can be stopped directly; Gradual reduction is required after more than 3 months, reducing the original dose by 25% every 5 days to avoid rebound inflammatory reactions.

(2) Adjustment for special populations

Patients with liver dysfunction have a 50% extension of medication discontinuation period, while those with renal dysfunction need to monitor fibrinogen levels for 2 weeks after discontinuation.

(3) Postoperative management

Discontinue medication at least 7 days before elective surgery, and immediately discontinue medication and supplement with vitamin K to counteract the risk of bleeding during emergency surgery.

3. Efficacy monitoring indicators

(1) Inflammatory indicators: CRP and ESR should be rechecked in the first and fourth weeks after discontinuation of medication, and any abnormal rebound should be considered for re treatment.

(2) Coagulation function: Fibrinogen levels should be maintained at 200-400mg/dL, and if below 150mg/dL, dosage reduction should be paused.

(3) Blood lipid profile: After stopping medication for 3 months, recheck TC and LDL-C. If the increase exceeds 20% of the baseline, restart treatment.